SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Nancy S. Reau, Eli J. Korner, Jian Han, Donald Jensen, Anemia Predicts Sustained Virological Response in Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C Treated with Peginterferon Alfa-2a and Ribavirin, Current Hepatology Reports, 2015, 14, 1, 53

    CrossRef

  2. 2
    Alan Gunderson, Adnan Said, Liver disease in kidney transplant recipients, Transplantation Reviews, 2015, 29, 1, 1

    CrossRef

  3. 3
    Sandra Bodeau, Eric Nguyen-Khac, Caroline Solas, Youssef Bennis, Dominique Capron, Gilles Duverlie, Etienne Brochot, Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations, The Journal of Clinical Pharmacology, 2015, 55, 4
  4. 4
    Robert Cheng, Thomas Tu, Nicholas Shackel, Geoffrey W McCaughan, Advances in and the future of treatments for hepatitis C, Expert Review of Gastroenterology & Hepatology, 2014, 8, 6, 633

    CrossRef

  5. 5
    Blaire E. Burman, Paul Y. Kwo, Kris V. Kowdley, Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity, Hepatology International, 2014, 8, 3, 352

    CrossRef

  6. 6
    EASL Clinical Practice Guidelines: Management of hepatitis C virus infection, Journal of Hepatology, 2014, 60, 2, 392

    CrossRef

  7. 7
    EASL Recommendations on Treatment of Hepatitis C 2014, Journal of Hepatology, 2014, 61, 2, 373

    CrossRef

  8. 8
    Imran Shahid, Waleed Hassan ALMalki, Muhammad Hassan Hafeez, Sajida Hassan, Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies, Critical Reviews in Microbiology, 2014, 1

    CrossRef

  9. 9
    Zobair M. Younossi, Mendel E. Singer, Heshaam M. Mir, Linda Henry, Sharon Hunt, Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients, Journal of Hepatology, 2014, 60, 3, 530

    CrossRef

  10. 10
    Jacinta A. Holmes, Stuart K. Roberts, Rachel J. Ali, Gregory J. Dore, William Sievert, Geoffrey W. McCaughan, Darrell H. Crawford, Wendy S. Cheng, Martin D. Weltman, Sara Bonanzinga, Kumar Visvanathan, Vijaya Sundararajan, Paul V. Desmond, D. Scott Bowden, Gail V. Matthews, Alexander J. Thompson, ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response, Hepatology, 2014, 59, 6
  11. 11
    Stefan Zeuzem, Ralph DeMasi, Alessandra Baldini, Bruce Coate, Donghan Luo, Joseph Mrus, James Witek, Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients, Journal of Hepatology, 2014, 60, 6, 1112

    CrossRef

  12. 12
    Jerome Rossert, Susan Yue, Karen Smirnakis, Daniel T. Mytych, Larry Johnson, Elias Kouchakji, Nicole Casadevall, Risk of Pure Red Cell Aplasia in Patients With Hepatitis C Receiving Antiviral Therapy and an Erythropoiesis-Stimulating Agent, Clinical Gastroenterology and Hepatology, 2014, 12, 2, 341

    CrossRef

  13. 13
    Audrey Coilly, Bruno Roche, Jérôme Dumortier, Vincent Leroy, Danielle Botta-Fridlund, Sylvie Radenne, Georges-Philippe Pageaux, Si-Nafaa Si-Ahmed, Olivier Guillaud, Teresa Maria Antonini, Stéphanie Haïm-Boukobza, Anne-Marie Roque-Afonso, Didier Samuel, Jean-Charles Duclos-Vallée, Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience, Journal of Hepatology, 2014, 60, 1, 78

    CrossRef

  14. 14
    Ezequiel Ridruejo, Safety of direct-acting antivirals in the treatment of chronic hepatitis C, Expert Opinion on Drug Safety, 2014, 13, 3, 307

    CrossRef

  15. 15
    Vincenza Conteduca, Domenico Sansonno, Sabino Russi, Fabio Pavone, Franco Dammacco, Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents, Journal of Infection, 2014, 68, 1, 1

    CrossRef

  16. 16
    Dominique Salmon-Ceron, Cédric Arvieux, Marc Bourlière, Patrice Cacoub, Philippe Halfon, Karine Lacombe, Georges-Philippe Pageaux, Gilles Pialoux, Lionel Piroth, Isabelle Poizot-Martin, Eric Rosenthal, Stanislas Pol, Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1, Liver International, 2014, 34, 6
  17. 17
    T. Jake Liang, Marc G. Ghany, Current and Future Therapies for Hepatitis C Virus Infection, New England Journal of Medicine, 2013, 368, 20, 1907

    CrossRef

  18. 18
    Thomas-Matthias Scherzer, Albert Friedrich Stättermayer, Rudolf Stauber, Andreas Maieron, Michael Strasser, Hermann Laferl, Remy Schwarzer, Christian Datz, Karoline Rutter, Sandra Beinhardt, Petra Steindl-Munda, Harald Hofer, Peter Ferenci, Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients, Journal of Hepatology, 2013, 59, 5, 964

    CrossRef

  19. 19
    Fred Poordad, Eric Lawitz, K. Rajender Reddy, Nezam H. Afdhal, Christophe Hézode, Stefan Zeuzem, Samuel S. Lee, Jose Luis Calleja, Robert S. Brown, Antonio Craxi, Heiner Wedemeyer, Lisa Nyberg, David R. Nelson, Lorenzo Rossaro, Luis Balart, Timothy R. Morgan, Bruce R. Bacon, Steven L. Flamm, Kris V. Kowdley, Weiping Deng, Kenneth J. Koury, Lisa D. Pedicone, Frank J. Dutko, Margaret H. Burroughs, Katia Alves, Janice Wahl, Clifford A. Brass, Janice K. Albrecht, Mark S. Sulkowski, Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection—A Randomized Trial, Gastroenterology, 2013, 145, 5, 1035

    CrossRef

  20. 20
    Waleed Hassan AlMalki, HCV infection: an enigma, recent advances and new paradigms for its treatment, Future Virology, 2013, 8, 4, 381

    CrossRef

  21. 21
    Peter W. Marks, Hematologic Manifestations of Liver Disease, Seminars in Hematology, 2013, 50, 3, 216

    CrossRef

  22. You have free access to this content22
    Angeli Chopra, Patricia L. Klein, Thia Drinnan, Samuel S. Lee, How to optimize HCV therapy in genotype 1 patients: management of side-effects, Liver International, 2013, 33,
  23. 23
    Christophe Hézode, Management of anaemia and other treatment complications, Digestive and Liver Disease, 2013, 45, S337

    CrossRef

  24. 24
    Manuel Romero-Gómez, Marina Berenguer, Esther Molina, José Luis Calleja, Management of anemia induced by triple therapy in patients with chronic hepatitis C: Challenges, opportunities and recommendations, Journal of Hepatology, 2013, 59, 6, 1323

    CrossRef

  25. 25
    G. N. Ioannou, J. D. Scott, Y. Yang, P. K. Green, L. A. Beste, Rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide study of 619 patients, Alimentary Pharmacology & Therapeutics, 2013, 38, 11-12
  26. 26
    Hari Shankar, Kian Bichoupan, Douglas T Dieterich, The pharmacokinetic evaluation of boceprevir for treatment of Hepatitis C virus, Expert Opinion on Drug Metabolism & Toxicology, 2013, 9, 12, 1647

    CrossRef